Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics released preliminary, unaudited 2025 results, expecting total revenue of approximately $145 million for the year, including license and royalty income. For the quarter ended December 31, 2025, it anticipates total revenue of about $33 million.
The company expects U.S. XPOVIO net product revenue of roughly $115 million for 2025, including about $32 million in the fourth quarter. Karyopharm also projects cash, cash equivalents, restricted cash and investments of around $64 million as of December 31, 2025, and believes its existing liquidity, together with expected XPOVIO sales and license revenue, will fund planned operations into the second quarter of 2026.
Karyopharm Therapeutics Inc. is calling a special virtual stockholder meeting on February 18, 2026 to vote on increasing its authorized capital. The company seeks to raise total authorized shares from 58,333,333 to 111,000,000 and authorized common stock from 53,333,333 to 106,000,000 to support future financing and strategic needs. As of December 23, 2025, 18,310,283 common shares were outstanding and 42,747,918 were issued or reserved, leaving 10,585,415 unreserved shares. Management explains that it is nearing the current limit, expects its existing cash and revenue to fund operations only into the second quarter of 2026, and that its ability to remain a going concern depends on raising additional capital. Stockholders will also vote on allowing adjournment of the meeting to solicit more proxies if support for the share increase is initially insufficient.
Karyopharm Therapeutics Inc. is registering up to 9,569,707 shares of common stock for resale by existing investors. These shares include stock already issued in recent financing transactions, shares issuable from pre-funded warrants, shares issuable from warrants with a $6.64 exercise price, and shares issuable upon conversion of its 9.00% Senior Convertible Notes due 2028. The company will not sell shares in this offering and will not receive proceeds from stockholder resales, though it would receive cash if investors exercise warrants. The registration fulfills contractual rights granted in October 2025 financings used to provide financial flexibility, additional working capital and to convert portions of maturing notes into equity.
Karyopharm Therapeutics Inc. is registering for resale up to 2,805,688 shares of common stock previously issued or issuable to institutional investors. This includes 1,487,917 outstanding shares sold in an October 2025 private placement and 1,317,771 shares issuable upon exercise of accompanying warrants. The company will not sell any new shares under this prospectus and will not receive proceeds from any resale, although it would receive cash if the warrants are exercised at their $6.64 per share exercise price.
In the October 2025 private placement, Karyopharm sold common stock and warrants at $5.880706 per share and warrant for gross proceeds of about $8.75 million. The warrants are exercisable until the earlier of 30 days after announcement of top-line Phase 3 XPORT-EC-042 endometrial cancer trial results for selinexor or October 10, 2028, and are subject to beneficial ownership limits. Karyopharm remains a commercial-stage oncology company focused on its lead drug XPOVIO (selinexor).
Karyopharm Therapeutics Inc. filed a resale registration covering up to 2,805,688 shares of common stock to be offered from time to time by selling stockholders. The registered amount consists of 1,487,917 outstanding shares and 1,317,771 shares issuable upon exercise of outstanding warrants.
The company is not selling any securities in this offering and will not receive proceeds from sales by the selling stockholders. Karyopharm would receive cash only if holders exercise warrants for shares at the stated exercise price. The shares may be sold through various customary methods and at market or negotiated prices.
As context, 17,050,876 shares were outstanding as of October 30, 2025
Karyopharm Therapeutics Inc. filed a resale registration covering up to 2,805,688 shares of common stock to be offered from time to time by selling stockholders. The registered amount consists of 1,487,917 outstanding shares and 1,317,771 shares issuable upon exercise of outstanding warrants.
The company is not selling any securities in this offering and will not receive proceeds from sales by the selling stockholders. Karyopharm would receive cash only if holders exercise warrants for shares at the stated exercise price. The shares may be sold through various customary methods and at market or negotiated prices.
As context, 17,050,876 shares were outstanding as of October 30, 2025
Karyopharm Therapeutics (KPTI) filed an S-3 prospectus for a resale of up to 9,569,707 shares of common stock by selling stockholders. The registration covers 949,908 shares already issued in recent financing transactions, 956,885 shares issuable upon exercise of outstanding pre-funded warrants, 4,950,947 shares issuable upon exercise of outstanding warrants with a $6.64 exercise price, and 2,711,967 shares issuable upon conversion of 9.00% Senior Convertible Notes due 2028, subject to customary limits.
The company stated it will not receive proceeds from sales by selling stockholders. It would receive cash only upon any cash exercises of warrants. The shares may be sold from time to time using methods described under “Plan of Distribution.”
As context, shares outstanding were 17,050,876 as of October 30, 2025. Examples of registered resale allocations include Braidwell Partners Master Fund LP 2,134,699 and Entities affiliated with Highbridge Capital Management, LLC 2,843,292.
Karyopharm Therapeutics (KPTI) filed an S-3 prospectus for a resale of up to 9,569,707 shares of common stock by selling stockholders. The registration covers 949,908 shares already issued in recent financing transactions, 956,885 shares issuable upon exercise of outstanding pre-funded warrants, 4,950,947 shares issuable upon exercise of outstanding warrants with a $6.64 exercise price, and 2,711,967 shares issuable upon conversion of 9.00% Senior Convertible Notes due 2028, subject to customary limits.
The company stated it will not receive proceeds from sales by selling stockholders. It would receive cash only upon any cash exercises of warrants. The shares may be sold from time to time using methods described under “Plan of Distribution.”
As context, shares outstanding were 17,050,876 as of October 30, 2025. Examples of registered resale allocations include Braidwell Partners Master Fund LP 2,134,699 and Entities affiliated with Highbridge Capital Management, LLC 2,843,292.
Karyopharm Therapeutics (KPTI) reported Q3 2025 results and flagged substantial doubt about continuing as a going concern. Revenue was $44.0 million (product $32.0 million; license/other $12.0 million, including Menarini milestones). Operating expenses fell year over year, but the company posted a net loss of $33.1 million and interest expense of $11.0 million in the quarter.
As of September 30, cash, cash equivalents and investments totaled $45.9 million. The balance sheet shows a senior secured term loan of $100.0 million, $116.0 million of 2029 convertible notes (principal), and a $73.5 million deferred royalty obligation. Management cited debt service, a minimum liquidity covenant and uncertain funding access in concluding there is substantial doubt about the company’s ability to continue as a going concern.
Subsequent to quarter-end (October 2025), the company executed financing transactions that included $27.5 million of new borrowings/convertible debt, $25.4 million of near-term payment deferrals, a temporary $15.0 million reduction of the minimum liquidity covenant, exchanges of 2025/2029 notes into equity and warrants, and a private placement raising ~$8.8 million.
Karyopharm Therapeutics (KPTI) reported Q3 2025 results and flagged substantial doubt about continuing as a going concern. Revenue was $44.0 million (product $32.0 million; license/other $12.0 million, including Menarini milestones). Operating expenses fell year over year, but the company posted a net loss of $33.1 million and interest expense of $11.0 million in the quarter.
As of September 30, cash, cash equivalents and investments totaled $45.9 million. The balance sheet shows a senior secured term loan of $100.0 million, $116.0 million of 2029 convertible notes (principal), and a $73.5 million deferred royalty obligation. Management cited debt service, a minimum liquidity covenant and uncertain funding access in concluding there is substantial doubt about the company’s ability to continue as a going concern.
Subsequent to quarter-end (October 2025), the company executed financing transactions that included $27.5 million of new borrowings/convertible debt, $25.4 million of near-term payment deferrals, a temporary $15.0 million reduction of the minimum liquidity covenant, exchanges of 2025/2029 notes into equity and warrants, and a private placement raising ~$8.8 million.
Karyopharm Therapeutics (KPTI) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025, and a previously announced, publicly available conference call to discuss the results and company updates.
The accompanying press release was furnished as Exhibit 99.1 and is incorporated by reference. The company noted that this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
Karyopharm Therapeutics (KPTI) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025, and a previously announced, publicly available conference call to discuss the results and company updates.
The accompanying press release was furnished as Exhibit 99.1 and is incorporated by reference. The company noted that this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
Karyopharm Therapeutics (KPTI) reported an insider equity award for its President and CEO, Richard Paulson, on 10/15/2025. He received 114,285 restricted stock units at $0 under the company’s 2022 Equity Incentive Plan. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the grant, Paulson’s beneficial ownership totaled 198,331 common shares, held directly. He is also listed as a director.
Karyopharm Therapeutics (KPTI) reported an insider equity grant on a Form 4. EVP, Chief Development Officer Stuart Poulton received 39,682 restricted stock units (RSUs) on 10/15/2025 under the company’s 2022 Equity Incentive Plan at a reported price of $0. The RSUs convert to common stock on a one‑for‑one basis and vest 100% on December 31, 2026.
Following the grant, his direct beneficial ownership was 67,392 shares. This filing documents a routine equity award to a company officer.